Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Value
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. [ Read More ]
The intrinsic value of one ASND stock under the Base Case scenario is 149.35 USD. Compared to the current market price of 151.17 USD, Ascendis Pharma A/S is Overvalued by 1%.
Valuation Backtest
Ascendis Pharma A/S
Run backtest to discover the historical profit from buying and selling ASND stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ascendis Eyes Enhanced Market Penetration
2023-Q3 Earnings Call
Ascendis Pharma posted a total revenue of €48 million for Q3 2023, almost entirely driven by its flagship product SKYTROFA, which generated €47 million. The firm's growth in the U.S. was significant, achieving low double-digit penetration among pediatric growth hormone deficiency (GHD) patients. To bolster its portfolio, Ascendis released interim results from ongoing clinical trials and increased its 2023 SKYTROFA revenue forecast to €170-175 million. Key upcoming milestones include a potential label expansion for SKYTROFA, pending Phase III data, and a resubmission of its NDA for TransCon PTH for hypoparathyroidism, with a European Commission decision expected soon.
Balance Sheet Decomposition
Ascendis Pharma A/S
Current Assets | 702.7m |
Cash & Short-Term Investments | 399.4m |
Receivables | 55.8m |
Other Current Assets | 247.5m |
Non-Current Assets | 122.9m |
Long-Term Investments | 5.7m |
PP&E | 110.6m |
Intangibles | 4.4m |
Other Non-Current Assets | 2.1m |
Current Liabilities | 197.3m |
Accounts Payable | 94.6m |
Other Current Liabilities | 102.8m |
Non-Current Liabilities | 773.9m |
Long-Term Debt | 618.9m |
Other Non-Current Liabilities | 155.1m |
Earnings Waterfall
Ascendis Pharma A/S
Revenue
|
266.7m
EUR
|
Cost of Revenue
|
-44.4m
EUR
|
Gross Profit
|
222.3m
EUR
|
Operating Expenses
|
-670m
EUR
|
Operating Income
|
-447.7m
EUR
|
Other Expenses
|
-33.7m
EUR
|
Net Income
|
-481.4m
EUR
|
Free Cash Flow Analysis
Ascendis Pharma A/S
What is Free Cash Flow?
ASND Profitability Score
Profitability Due Diligence
Ascendis Pharma A/S's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Ascendis Pharma A/S's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ASND Solvency Score
Solvency Due Diligence
Ascendis Pharma A/S's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Ascendis Pharma A/S's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ASND Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for ASND is 175.64 USD with a low forecast of 117.16 USD and a high forecast of 236.25 USD.
Shareholder Return
ASND Price
Ascendis Pharma A/S
Average Annual Return | 2.03% |
Standard Deviation of Annual Returns | 19.35% |
Max Drawdown | -62% |
Market Capitalization | 8.7B USD |
Shares Outstanding | 56 614 400 |
Percentage of Shares Shorted | 7.63% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The firm is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
Contact
IPO
Employees
Officers
The intrinsic value of one ASND stock under the Base Case scenario is 149.35 USD.
Compared to the current market price of 151.17 USD, Ascendis Pharma A/S is Overvalued by 1%.